Novalgina: What's It For? - Step To Health
 

Novalgina: What's It For?

Novalgina is used in the treatment of acute moderate or severe postoperative or post-traumatic pain, colic, or tumor pain.
Novalgina: What's It For?

Last update: 29 December, 2021

Novalgina is a medicine composed of metamizole or dipyrone. It belongs to the pyrazolone group and has analgesic and antipyretic action.

However, Novalgina also has anti-inflammatory and spasmolytic properties, although less potent. Here are some of the characteristics of this drug.

How does Novalgina work?

Like other drugs in the group, dipyrone or metamizole acts by inhibiting the action of cyclooxygenase. It inhibits the synthesis of prostaglandins, which causes its analgesic and antipyretic properties.

However, despite this, and the fact that its metabolites are also active and block the synthesis of prostaglandins, its anti-inflammatory activity isn’t significant.

On the other hand, it relaxes and reduces gastrointestinal and uterine smooth muscle activity. It can be used orally, intramuscularly, or intravenously.

Novalgina is rapidly metabolized in the liver, where it’s converted to active metabolites that are excreted in the urine.

What’s Novalgina used for?

Novalgine is a drug used in the treatment of moderate to severe acute postoperative or post-traumatic pain, colic, or pain due to tumors. It’s also prescribed in cases of a high fever that doesn’t respond to other measures or other antipyretic drugs.

You may also be interested in: What Are the Treatment Options for Chronic Pain?

Dosage and contraindications

Some pills.

The dosage of Novalgina will depend on the analgesic effect sought and the patient’s situation. In general, for adults, the usual oral administration is between 8 and 16 mg per kg of body weight.

Parenteral administration is associated with an increased risk of anaphylactic reactions. For the treatment of fever in children, a dose of 10 mg/kg body weight is usually sufficient.

The analgesic and antipyretic effects of Novalgina occur within 30 and 60 minutes of administration. Parenteral doses of more than 1 gram of dipyrone should be carefully considered because of the risk of hypotension.

Another recommendation to be taken into account is that, for diabetic patients, tablets or drops should be used instead of syrup. In addition, high doses of metamizole should be avoided in patients with renal or hepatic insufficiency.

As for contraindications, Novalgina shouldn’t be used in the following situations:

In addition, hematological assessment is advised before treatment, and also periodically during treatment.

Adverse reactions of Novalgina

The components of Novalgina, dipyrone or metamizole, are analgesics which, because of their toxic effects – especially their association with agranulocytosis – have been withdrawn from the market in many countries. There’s information that suggests that its use results in severe hypersensitivity reactions. These include:

  • Agranulocytosis: Although this is rare, it’s a serious and sometimes irreversible reaction. However, even though its origin is unknown, it’s considered to be an immunological reaction.
    • Marián García, Doctor in Pharmacy and author, states: “there’s a significant genetic component that predisposes to suffer from agranulocytosis and it seems that in our country [Spain] we’re more protected. In fact, some studies show that there’s a significant percentage of foreign people who suffer from it in our country”.
  • Shock: This is another hypersensitivity reaction. It’s manifested by pruritus, cold sweats, drowsiness, nausea, dyspnea, and skin discoloration.
  • In addition, cutaneous hypersensitivity reactions may occur, especially in the mucous membranes of the eyes and in the nasopharyngeal region. Other reactions that may occur with metamizole administration are leucopenia, thrombocytopenia, and hemolytic anemia.
  • Hypotension: It may occur particularly in patients with pre-existing hypotension, or with hypovolaemia, dehydration, high fever, circulatory failure, coronary heart disease, stenosis of cerebral blood vessels, or cerebral vasospasm.

Agranulocytosis and shock are life-threatening and require discontinuation of Novalgina treatment. In these cases, you should receive immediate medical attention.

On the other hand, there’s an increased risk of this type of reaction in patients with any of the following conditions or diseases: intolerance to alcohol, intolerance to dyes and/or preservatives; chronic urticaria, and bronchial asthma, especially if there’s polyposis rhinosinusitis.

Recommendations to healthcare professionals

The Spanish Agency of Medicines and Health Products has reviewed the situation of metamizole in Spain due to the notification of the cases of agranulocytosis. They remind us that these drugs are prescription medicines. It also makes the following recommendations to health professionals:

  • Use metamizole only for treatments of short duration, 7 days at most.
  • Use only in cases that it’s authorized for, and use the minimum effective doses.

However, if a more prolonged treatment is necessary, periodic hematological controls should be carried out, including leukocyte formula. In patients in whom monitoring isn’t possible, Novalgina or metamizole, in any form, should not be used.

Discover more here: Non-Acid Non-Opioid Analgesics

An important recommendation

Experts recommend that, before prescribing Novaligina or metamizole, doctors should take a detailed medical history of the patient. In this way, its use can be avoided in patients with a history of hypersensitivity or hematological reactions to this drug.

It might interest you...
Can I Calm Neuropathic Pain With Essential Oils?
Step To Health
Read it in Step To Health
Can I Calm Neuropathic Pain With Essential Oils?

Essential oils have properties that can be useful for treating neuropathic pain. But, are they effective? Keeo reading to find out!



  • AEMPS. Ficha Técnica (Metamizol) [Internet]. 2021 [Consultado: 28-12-2021]. URL disponible en: https://cima.aemps.es/cima/pdfs/es/ft/63430/63430_ft.pdf
  • Escobar, W., Ramirez, K., Avila, C., Limongi, R., Vanegas, H., & Vazquez, E. (2012). Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats. European Journal of Pain. https://doi.org/10.1002/j.1532-2149.2011.00057.x

  • Grossman, R., Ram, Z., Perel, A., Yusim, Y., Zaslansky, R., & Berkenstadt, H. (2007). Control of postopertive pain after awake craniotomy with local intradermal analgesia and metamizol. Israel Medical Association Journal.

  • Güttler, K. (2015). Metamizol. Schmerz. https://doi.org/10.1007/s00482-015-1520-0